Search | Clinical Trials Finder

Conditions: Anal Cancer, Nonneoplastic Condition, Penile Cancer, Precancerous Condition
Interventions: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, laboratory biomarker analysis; Biological · Other
Lead sponsor: AIDS Malignancy Consortium; Network
Eligibility: 13 Years to 26 Years · Male only
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 18
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 10 more

Conditions: Healthy Donors, HIV Positive
Interventions: collection of follow-up sample based on PRISM HIV O Plus result; Device
Lead sponsor: Abbott Diagnostics Division; Industry
Eligibility: 17 Years and older
Enrollment: 24,111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Davenport, Iowa • Kansas City, Missouri • Dayton, Ohio + 4 more

Conditions: Candidiasis, Oral, HIV Infections
Interventions: Chlorhexidine gluconate; Drug
Lead sponsor: Procter and Gamble; Industry
Eligibility: 13 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Columbus, Ohio + 1 more

Conditions: HIV Infections, Staphylococcal Infections
Interventions: Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%, Placebo; Drug
Lead sponsor: Henry M. Jackson Foundation for the Advancement of Military Medicine; Other
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 4
States / cities: San Diego, California • Bethesda, Maryland • San Antonio, Texas + 1 more

Conditions: HIV-1 Infection
Interventions: F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 34
States / cities: Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more

Conditions: Smoking, HIV Infections
Interventions: Varenicline tartrate, Nicotine Replacement Therapy, Biological Control, Motivational Interview; Drug · Other · Behavioral
Lead sponsor: Philip Diaz; Other
Eligibility: 18 Years and older
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: HIV Infections, Tuberculosis
Interventions: Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1997
U.S. locations: 25
States / cities: San Francisco, California • Denver, Colorado • New Haven, Connecticut + 15 more

Conditions: AIDS Dementia Complex, HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 12
States / cities: Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 6 more

Conditions: HIV, HIV Infections
Interventions: E/C/F/TAF, E/C/F/TDF, E/C/F/TDF Placebo, E/C/F/TAF Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 872 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 78
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more

Conditions: HIV Positive, Marijuana Smoking
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HIV Infections
Interventions: Tucaresol; Drug
Lead sponsor: Aaron Diamond AIDS Research Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 3,669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2006
U.S. locations: 91
States / cities: Mill Valley, California • Oakland, California • San Francisco, California + 31 more

Conditions: HIV/AIDS, Clinical Depression
Interventions: Zaleplon; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections, Renal Transplant Rejection
Interventions: BIC/F/TAF 50Mg-200Mg-25Mg Tablet; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions: Bictegravir, emtricitabine, and tenofovir alafenamide; Drug
Lead sponsor: CAN Community Health; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more

Conditions: Tuberculosis
Interventions: Not listed
Lead sponsor: Cepheid; Industry
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Efavirenz, Stavudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: San Diego, California • Dallas, Texas

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Clarithromycin, Rifabutin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 12 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • Oakland, California + 24 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Delavirdine mesylate, Zidovudine; Drug
Lead sponsor: Pharmacia and Upjohn; Industry
Eligibility: 14 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • San Francisco, California • New York, New York + 3 more

Conditions: HIV, Pneumococcal Infections, Pneumococcal Vaccines
Interventions: PCV-13, PPSV-23; Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2021
U.S. locations: 3
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Unsafe Sex
Interventions: 1-session of telephone-administered motivational interviewing, 4-session telephone-administered motivational interviewing; Behavioral
Lead sponsor: Ohio University College of Osteopathic Medicine; Other
Eligibility: 45 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Athens, Ohio

Conditions: HIV Infections, Pregnancy
Interventions: Nelfinavir mesylate, Lamivudine, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 7
States / cities: Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 3 more

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: Chiron Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 23
States / cities: Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 18 more

Conditions: HIV Infections, Tuberculosis
Interventions: Isoniazid, Pyridoxine hydrochloride; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 10 more

Search by objective public record fields.

Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males

Evaluation of a Human Immunodeficiency Virus (HIV) Blood Screening Assay

The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients

Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

Smoking Cessation Using Motivational Therapy and Varenicline

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

An Open Trial of Zidovudine (AZT) Treatment of the AIDS Dementia Complex in Patients With AIDS or Low CD4+ Lymphocyte Counts

Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults

Medical Marijuana Use in HIV+ Patients Prospective Cohort Study

A Study of Tucaresol in HIV-Infected Patients Who Are Taking Other Anti-HIV Drugs

A Study of the Long-Term Outcomes of HIV-Positive Patients

Zaleplon in HIV Patients With Depression

Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in Pulmonary Tuberculosis Suspects

A Study of an Adherence Plan to Help HIV-Positive Patients Take Their First Anti-HIV Medications Correctly

The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients

A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients

Mechanisms of Impaired HIV-associated B Cell and Pneumococcal Vaccine Responses

Telephone-delivered Behavioral Interventions to Reduce Risky Sexual Behavior in HIV-positive Late Middle-age and Older Adults

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy

Prophylaxis Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Suspected Latent Tuberculous Infection